MARK FISHER 

Mark Fisher joins Sutro Biopharma with over 25 years of clinical operations experience, specializing in oncology-focused investigational programs across all phases of clinical development. He has been responsible for developing successful global clinical operations strategies, building high-performing clinical operations teams, and, most recently, serving as the Head of Hematology/Oncology Clinical Operations at AstraZeneca, where he also acted as the West Coast site head.

Mark has held senior leadership positions at Acerta Pharma, Gilead, and Roche/Genentech. He brings extensive experience in global regulatory inspections and audits, with a strong focus on ensuring inspection readiness for global registrational filings. His primary therapeutic areas of expertise include oncology, hematology/oncology, immuno-oncology (IO), and cell therapy. Mark has been instrumental in securing successful regulatory filings for several marketed products, including Rituxan/MabThera, Xeloda, Venclexta, Calquence, Polatuzimab, Gazya, and Avastin. Mark is also a retired, service-decorated U.S. Navy veteran and holds a B.S. in Molecular Biology/Biochemistry from San Francisco State University.